New ultrasound technique could eliminate need for contrast dye in pancreatic cyst exams
NCT ID NCT07663734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study investigates whether a new ultrasound technology called Superb Microvascular Imaging (SMI) can accurately analyze material inside pancreatic cysts (PIMPTs) without using a contrast agent. Currently, doctors inject a contrast dye during endoscopic ultrasound to assess cancer risk. SMI may provide similar information without the injection. The trial will enroll 60 patients with pancreatic cysts and compare SMI results to standard contrast-enhanced imaging.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Superb Microvascular Imaging (SMI) ultrasound
- What this could lead to
- If successful, SMI could replace contrast injections for evaluating pancreatic cysts, making the procedure faster and safer.
- What could go wrong
- This is an early exploratory study with no prior data on SMI for this use. The technique may not be accurate enough to replace current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient referred for an endoscopic ultrasound assessment of a PIMPT * Patient with endocystic material of undetermined nature measuring 3 mm or more * Patient registered with or covered by the social security scheme * Patient who speaks French * Patient who has signed an informed consent form Exclusion Criteria: * Patient whose lesion meets the criteria for malignancy (tissue mass, metastases, ascites, vascular infiltration) * Patient for whom Sonovue is contraindicated * Pregnant woman * Vulnerable patient: an adult under guardianship, curatorship or other legal protection, or deprived of their liberty by a judicial or administrative decision * Patient admitted to hospital without consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Papillary and mucinous intraductal tumours of the pancreas are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Privé Jean Mermoz
Lyon, 69008, France